Lifordi Immunotherapeutics
MA - BurlingtonBiotechnology
Focus: Lifordi Immunotherapeutics is a biotechnology company specializing in antibody-drug conjugate (ADC) delivery platforms for immunology indications. The company is early-stage with a single Phase 1 program and appears to be pre-revenue.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
Open Jobs
0
About Lifordi Immunotherapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Lifordi Immunotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
LFD-200
Rheumatoid ArthritisClinical Trials (1)
NCT07207954Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis
Phase 1Help build intelligence for Lifordi Immunotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.